Volume 84, Issue 2, Pages (August 2013)

Slides:

Advertisements

Similar presentations

Volume 77, Issue 9, Pages (May 2010)

Advertisements

Volume 81, Issue 2, Pages (January 2012)

Volume 74, Issue 12, Pages (December 2008)

Volume 54, Issue 2, Pages (August 1998)

Volume 70, Issue 10, Pages (November 2006)

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Anemia management in chronic kidney disease

Tuberculosis and tubulointerstitial nephritis: an intriguing puzzle

Volume 85, Issue 3, Pages (March 2014)

The Case ∣ Acute renal failure and anemia

Efficacy and Safety of Abelmoschus manihot for Primary Glomerular Disease: A Prospective, Multicenter Randomized Controlled Clinical Trial Li Zhang,

Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia Lan-Ping Xu, Zheng-Li Xu, Xiao-Hui Zhang, Huan.

Volume 86, Issue 6, Pages (December 2014)

Prehypertension and chronic kidney disease: the ox or the plow?

Reassessment of the care of the patient with chronic kidney disease

Volume 94, Issue 5, Pages (November 2018)

Volume 74, Issue 12, Pages (December 2008)

Volume 80, Issue 10, Pages (November 2011)

John P. Middleton, Patrick H. Pun Kidney International

Nonmalignant Late Effects in Survivors of Partially Matched Donor Hematopoietic Stem Cell Transplantation Xiao-Dong Mo, Lan-Ping Xu, Dai-Hong Liu, Xiao-Hui.

Kumar Sharma, Ljiljana Paša-Tolić Kidney International

Rutger J.H. Maas, Jack F.M. Wetzels, Jeroen K.J. Deegens

Volume 77, Issue 8, Pages (April 2010)

Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial Jeroen K.J. Deegens, Jack F.M. Wetzels

Steven J. Chadban, Natalie D. Staplin Kidney International

How to interpret the eGFR in patients with small body surface area

Serum-soluble urokinase receptor concentration in primary FSGS

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity Juan Zhao, Zhao Cui, Rui Yang,

Volume 73, Issue 7, Pages (April 2008)

Volume 77, Issue 2, Pages (January 2010)

Volume 84, Issue 3, Pages (September 2013)

Volume 71, Issue 11, Pages (June 2007)

R. Rajakariar, E.J. Sharples, M.J. Raftery, M. Sheaff, M.M. Yaqoob

Volume 73, Issue 11, Pages (June 2008)

The calcium–phosphorus in guidelines for CKD-MBD

Volume 79, Issue 6, Pages (March 2011)

Volume 85, Issue 3, Pages (March 2014)

Volume 76, Issue 5, Pages (September 2009)

Effects of hemodialysis on cardiac function

Volume 69, Issue 5, Pages (March 2006)

Volume 72, Issue 12, Pages (December 2007)

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 85, Issue 3, Pages (March 2014)

Volume 87, Issue 1, Pages (January 2015)

Volume 77, Issue 9, Pages (May 2010)

Alternate-day dialysis may be needed for hemodialysis patients

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Nephrology Crossword: Glomerulonephritis

Volume 69, Issue 8, Pages (April 2006)

Volume 71, Issue 4, Pages (February 2007)

Volume 85, Issue 5, Pages (May 2014)

Antiglomerular basement membrane disease with normal renal function

A man with a hole in his penis

Volume 87, Issue 5, Pages (May 2015)

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

The treatment of acute interstitial nephritis: More data at last

Volume 55, Pages S3-S16 (June 1999)

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

The hypothesis that abnormal BH4 metabolism impairs kidney function

Reappraisal of melamine exposure and adult calcium urolithiasis

Volume 86, Issue 5, Pages (November 2014)

Membranous nephropathy: recent travels and new roads ahead

Laura M. Krinsky, William J. Levine Kidney International

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis Eero O. Honkanen, Anna-Maija Teppo, Carola.

Presentation transcript:

Volume 84, Issue 2, Pages 366-372 (August 2013) Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis Jing Huang, Gang Liu, Yi-Miao Zhang, Zhao Cui, Fang Wang, Xiao-Jing Liu, Rong Chu, Ying Chen, Ming-Hui Zhao Kidney International Volume 84, Issue 2, Pages 366-372 (August 2013) DOI: 10.1038/ki.2013.55 Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 1 Plasma soluble urokinase-type plasminogen activator receptor (suPAR) levels among patients with primary focal segmental glomerulosclerosis (FSGS), normal subjects, and patients with minimal change disease, membranous nephropathy, and secondary FSGS. Kidney International 2013 84, 366-372DOI: (10.1038/ki.2013.55) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 2 The plasma soluble urokinase-type plasminogen activator receptor (suPAR) levels in primary focal segmental glomerulosclerosis (FSGS) patients with different pathological variants. NOS, not otherwise specified. Kidney International 2013 84, 366-372DOI: (10.1038/ki.2013.55) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 3 The correlations between plasma soluble urokinase-type plasminogen activator receptor (suPAR) level and creatinine clearance rate for the individual glomerular disease. (a) Patients with primary focal segmental glomerulosclerosis (FSGS), (b) patients with minimal change disease, (c) patients with membranous nephropathy, and (d) patients with secondary FSGS. Kidney International 2013 84, 366-372DOI: (10.1038/ki.2013.55) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 4 The changes in plasma soluble urokinase-type plasminogen activator receptor (suPAR) level in patients with primary focal segmental glomerulosclerosis (FSGS) during follow-up. (a) Patients with complete remission, (b) patients with partial remission, and (c) patients with treatment failure. Kidney International 2013 84, 366-372DOI: (10.1038/ki.2013.55) Copyright © 2013 International Society of Nephrology Terms and Conditions